Gene: B4GALNT4
Official Full Name: beta-1,4-N-acetyl-galactosaminyltransferase 4provided by HGNC
Gene Summary: Enables acetylgalactosaminyltransferase activity. Predicted to be located in Golgi cisterna membrane. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO19497 | B4GALNT4 Knockout cell line (HeLa) | Human | B4GALNT4 | 1:3~1:6 | Negative | Online Inquiry |
KO19498 | B4GALNT4 Knockout cell line (HCT 116) | Human | B4GALNT4 | 1:2~1:4 | Negative | Online Inquiry |
KO19499 | B4GALNT4 Knockout cell line (HEK293) | Human | B4GALNT4 | 1:3~1:6 | Negative | Online Inquiry |
KO19500 | B4GALNT4 Knockout cell line (A549) | Human | B4GALNT4 | 1:3~1:4 | Negative | Online Inquiry |
B4GALNT4 Gene Knockout Cell Lines are specialized biological tools designed for researchers studying the function and implications of the B4GALNT4 gene, which encodes a glycosyltransferase involved in the synthesis of glycoconjugates. These cell lines are engineered using CRISPR/Cas9 technology to create targeted disruptions in the B4GALNT4 gene, facilitating a deeper understanding of the gene's role in cellular processes and disease mechanisms.
The primary function of B4GALNT4 is to catalyze the transfer of N-acetylgalactosamine to specific substrates, influencing glycan biosynthesis pathways crucial for cell signaling, adhesion, and immune responses. By utilizing these knockout cell lines, researchers can elucidate the downstream effects of B4GALNT4 disruption on cellular behavior, including changes in glycosylation patterns, receptor interactions, and overall cellular phenotype. This research is vital for understanding various disease contexts, including cancer and genetic disorders where glycosylation plays a pivotal role.
In comparison to other available tools, B4GALNT4 Knockout Cell Lines offer a highly specific and reproducible model for functional studies. Their unique advantage lies in the precise ablation of the B4GALNT4 gene, which enables researchers to conduct targeted assays and functional studies with greater accuracy than traditional knockdown approaches, which may produce incomplete or off-target effects. This specificity enhances the reliability of experimental results, making them an invaluable asset in both research and clinical applications.
For researchers and clinicians exploring the intricacies of gene function and disease mechanisms, these knockout cell lines pave the way for new discoveries and therapeutic strategies. They provide a powerful platform for studying cell biology and therapeutic interventions at a molecular level, thus enhancing the potential for breakthroughs in medical science.
Our company specializes in the development of innovative and precise genetic models tailored for advanced research applications. With a commitment to scientific excellence, we deliver high-quality tools that empower researchers to push the boundaries of knowledge in their fields.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.